Investor Relations
Welcome to Alzinova AB’s IR pages.
Alzinova AB is a company specializing in the treatment of Alzheimer’s disease – one of our major health scourges, without effective treatment options.
Latest press releases
- 2021-09-30 | Regulatory Alzinova receives approval to start the first clinical study with the oligomer-specific ALZ-101 vaccine in patients with Alzheimer’s disease
- 2021-08-26 | Regulatory Alzinova AB interim report January – June 2021
Latest news
- 2021-10-14 Alzinova at Redeye Neurology (CNS) Seminar October 13th
- 2021-10-11 Alzinova Presented at Aktiedagen